Current challenges in HER2-positive breast cancer

被引：28

作者：

Puglisi, Fabio ^{[1
,2
]}

Fontanella, Caterina ^{[1
,2
]}

Amoroso, Vito ^{[3
]}

Bianchi, Giulia Valeria ^{[4
]}

Bisagni, Giancarlo ^{[5
]}

Falci, Cristina ^{[6
]}

Fontana, Andrea ^{[7
]}

Generali, Daniele ^{[8
]}

Gianni, Lorenzo ^{[9
]}

Grassadonia, Antonio ^{[10
]}

Moscetti, Luca ^{[11
]}

Portarena, Ilaria ^{[12
]}

Rossi, Emanuela ^{[13
]}

Marchetti, Paolo ^{[14
,15
]}

机构：

[1] Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy

[2] Univ Hosp Udine, Dept Oncol, Piazzale SM Misericordia, I-33100 Udine, Italy

[3] Spedali Civili Hosp, Dept Oncol, Brescia, Italy

[4] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[5] Arcispedale Santa Maria Nuova Hosp, Dept Oncol, Reggio Emilia, Italy

[6] IOV IRCCS, Div Med Oncol 2, Veneto Istitute Oncol, Padua, Italy

[7] Hosp & Univ Pisa, Dept Oncol, Pisa, Italy

[8] Univ Trieste, Dipartimento Univ Clin Sci Med Chirurg & Salute, Tieste, Italy

[9] Infermi Hosp, Dept Oncol, Rimini, Italy

[10] Univ G DAnnunzio, Dept Oncol, SS Annunziata Hosp, Chieti, Italy

[11] Belcolle Hosp, Dept Oncol, Viterbo, Italy

[12] Univ Roma Tor Vergata, Dept Oncol, Rome, Italy

[13] SG Moscati Hosp, Dept Oncol, Avellino, Italy

[14] Univ Roma La Sapienza, Fac Med & Psicol, Osped St Andrea, Piazzale Aldo Moro 5, I-00185 Rome, Italy

[15] IRCCS, IDI, Rome, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2016年 / 98卷

关键词：

Breast cancer; Dual targeting; HER2; Lapatinib; Neoadjuvant; Pertuzumab; Trastuzumab; Trastuzumab-emtansine; INTERNATIONAL EXPERT CONSENSUS; CHEMOTHERAPY PLUS TRASTUZUMAB; CONTROLLED SUPERIORITY TRIAL; SURGICAL ADJUVANT BREAST; PRIMARY SYSTEMIC THERAPY; OPEN-LABEL; NEOADJUVANT THERAPY; FOLLOW-UP; PREOPERATIVE CHEMOTHERAPY; PATHOLOGICAL RESPONSE;

D O I：

10.1016/j.critrevonc.2015.10.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The introduction of trastuzumab into routine clinical practice has had a dramatic effect on the outlook for patients with HER2-positive breast cancer. Nevertheless, answers to some long unresolved questions about the optimal use of trastuzumab (such as its role in small tumors or low-risk disease, cardiac safety in the elderly, and treatment duration) have emerged only relatively recently. Moreover, with the availability of new highly effective HER2-directed therapies, including pertuzumab and trastuzumab-emtansine (T-DM1), the treatment algorithm for HER2-positive breast cancer continues to evolve. This review provides a summary of the latest evidence providing insight into the management of early and advanced HER2-positive breast cancer and delineates future perspectives of study and treatment for these patients. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：211 / 221

页数：11

共 110 条

[1] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].

Albain, K. ;

Anderson, S. ;

Arriagada, R. ;

Barlow, W. ;

Bergh, J. ;

Bliss, J. ;

Buyse, M. ;

Cameron, D. ;

Carrasco, E. ;

Clarke, M. ;

Correa, C. ;

Coates, A. ;

Collins, R. ;

Costantino, J. ;

Cutter, D. ;

Cuzick, J. ;

Darby, S. ;

Davidson, N. ;

Davies, C. ;

Davies, K. ;

Delmestri, A. ;

Di Leo, A. ;

Dowsett, M. ;

Elphinstone, P. ;

Evans, V. ;

Ewertz, M. ;

Gelber, R. ;

Gettins, L. ;

Geyer, C. ;

Goldhirsch, A. ;

Godwin, J. ;

Gray, R. ;

Gregory, C. ;

Hayes, D. ;

Hill, C. ;

Ingle, J. ;

Jakesz, R. ;

James, S. ;

Kaufmann, M. ;

Kerr, A. ;

MacKinnon, E. ;

McGale, P. ;

McHugh, T. ;

Norton, L. ;

Ohashi, Y. ;

Paik, S. ;

Pan, H. C. ;

Perez, E. ;

Peto, R. ;

Piccart, M. .

LANCET, 2012, 379 (9814) :432-444

[2] Prognosis and Outcome of Small (≤1 cm), Node-Negative Breast Cancer on the Basis of Hormonal and HER-2 Status [J].

Amar, Surabhi ;

McCullough, Ann E. ;

Tan, Winston ;

Geiger, Xochiquetzal J. ;

Boughey, Judy C. ;

McNeil, Rebecca B. ;

Coppola, Kyle E. ;

McLaughlin, Sarah A. ;

Palmieri, Frances M. ;

Perez, Edith A. .

ONCOLOGIST, 2010, 15 (10) :1043-1049

[3]

[Anonymous], BREAST CANC RES T S1

[4]

[Anonymous], 2013 SAN ANT BREAST

[5]

[Anonymous], CLIN BREAST CANC

[6]

[Anonymous], J CLIN ONCOL S

[7]

[Anonymous], ANN ONCOL S4

[8] Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01) [J].

Azim, Hatem A., Jr. ;

Metzger-Filho, Otto ;

de Azambuja, Evandro ;

Loibl, Sibylle ;

Focant, Florine ;

Gresko, Ekaterina ;

Arfi, Mounir ;

Piccart-Gebhart, Martine .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (01) :387-391

[9] Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy [J].

Bader, Arnim A. ;

Schlembach, Dietmar ;

Tamussino, Karl F. ;

Pristauz, Gunda ;

Petru, Edgar .

LANCET ONCOLOGY, 2007, 8 (01) :79-81

[10] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].

Baselga, Jose ;

Bradbury, Ian ;

Eidtmann, Holger ;

Di Cosimo, Serena ;

de Azambuja, Evandro ;

Aura, Claudia ;

Gomez, Henry ;

Dinh, Phuong ;

Fauria, Karine ;

Van Dooren, Veerle ;

Aktan, Gursel ;

Goldhirsch, Aron ;

Chang, Tsai-Wang ;

Horvath, Zsolt ;

Coccia-Portugal, Maria ;

Domont, Julien ;

Tseng, Ling-Min ;

Kunz, Georg ;

Sohn, Joo Hyuk ;

Semiglazov, Vladimir ;

Lerzo, Guillermo ;

Palacova, Marketa ;

Probachai, Volodymyr ;

Pusztai, Lajos ;

Untch, Michael ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine .

LANCET, 2012, 379 (9816) :633-640

← 1 2 3 4 5 6 7 8 9 10 →